Stock YB3 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Shin Nippon Biomedical Laboratories, Ltd. BOERSE MUENCHEN

Equities

YB3

JP3379950003

Real-time BOERSE MUENCHEN
Other stock markets
 01:13:44 02/07/2024 am IST 		5-day change 1st Jan Change
8.2 EUR -2.38% Intraday chart for Shin Nippon Biomedical Laboratories, Ltd. +1.82% -22.22%
08/05 Shin Nippon Biomedical Laboratories, Ltd. Announces Fiscal Year End Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 25, 2024; Provides Second Quarter End and Fiscal Year End Dividend Guidance for the Fiscal Year Ended March 31, 2025 CI
08/05 Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Forecasts for the Six Months Ending September 30, 2024 and Year Ending March 31, 2025 CI

Strengths

  • The group's high margin levels account for strong profits.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company is in debt and has limited leeway for investment
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. Stock Shin Nippon Biomedical Laboratories, Ltd.
-22.22% 369M -
MODERNA, INC. Stock Moderna, Inc.
+16.59% 45.51B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-9.89% 38.52B
B
LONZA GROUP AG Stock Lonza Group AG
+38.08% 38.13B
A
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+27.12% 30.74B
B
CELLTRION, INC. Stock Celltrion, Inc.
-8.64% 26.03B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.81% 25.92B
B-
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+45.08% 14.13B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.85% 12.73B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.19% 11.29B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 2395 Stock
  4. YB3 Stock
  5. Ratings Shin Nippon Biomedical Laboratories, Ltd.